Acta Med. 2021, 64: 187-192

Oral Ibandronate Therapy in Three Patients with Osteogenesis Imperfecta

Štěpán Kutíleka,b,c, Ivana Plášilováa,c, Sylva Skálováa, Milan Bayera,d, Erika Ondrušováa

aDepartment of Pediatrics, Faculty of Medicine and Faculty Hospital in Hradec Králové, Charles University, Hradec Králové, Czech Republic
bDepartment of Pediatrics, Klatovy Hospital, Klatovy, Czech Republic
cDepartment of Pediatrics, Pardubice Hospital, Pardubice, Czech Republic
dDepartment of Pediatrics, 3rd Faculty of Medicine and University Hospital Královské Vinohrady, Charles University in Prague, Czech Republic

Received December 13, 2019
Accepted August 12, 2021

Introduction: Treatment with orally administered ibandronate is an effective way to increase bone mineral density (BMD) and reduce fracture rate in post-menopausal women and in men with osteoporosis. There are only very few reports concerning ibandronate therapy in children and adolescents, and in patients with osteogenesis imperfecta (OI), as bisphosphonates are not registered for therapeutic use in pediatrics. Case Report: We present three patients with OI, where once-monthly oral ibandronate increased spinal BMD after two and four years, respectively, of therapy without any occurrence of new fractures and no adverse reactions. Somatic growth was not affected by the ibandronate treatment. Conclusion: Once-monthly oral ibandronate increased BMD and most probably improved bone quality in young patients with OI.


This work was presented at The 9th International Conference on Children’s Bone Health (ICCBH), June 22–25 2019; Salzburg, Austria.


15 live references